Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,017 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Systemic Infection Clear all

Conditions: Shock, Sepsis, Hypotension, Critical Illness
Interventions: Tranexamic Acid, Control Intervention (Carrier fluid only); Drug
Lead sponsor: San Diego Veterans Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Staphylococcal Sepsis
Interventions: Pagibaximab (formerly BSYX-A110); Drug
Lead sponsor: Biosynexus Incorporated; Industry
Eligibility: 48 Hours to 120 Hours
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atrophy, Sepsis, Weakness
Interventions: Not listed
Lead sponsor: Gregory A. Schmidt; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Sepsis, Shock
Interventions: Tissue oxygenation monitoring; Device
Lead sponsor: University of Michigan; Other
Eligibility: 30 Days to 18 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: COVID-19
Interventions: Baricitinib; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Complication of Prematurity, Immunologic Deficiency Syndromes
Interventions: Adjuvant, Blood Collection; Other
Lead sponsor: University of Florida; Other
Eligibility: Up to 55 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Sepsis
Interventions: Not listed
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sepsis, Disseminated Intravascular Coagulation
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bacteremia
Interventions: No intervention; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 1,354 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sepsis
Interventions: Blood samples collected; Procedure
Lead sponsor: Abbott RDx Cardiometabolic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 24
States / cities: Los Angeles, California • Sylmar, California • Denver, Colorado + 16 more

Conditions: Airway Control, Anesthesia, Intubation, Complication
Interventions: Ketamine, Etomidate; Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Leukemia, Lymphoma
Interventions: anti-thymocyte globulin, melphalan, antiviral therapy, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cancer, Bacteremia
Interventions: Not listed
Lead sponsor: CAMC Health System; Other
Eligibility: Up to 17 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Pediatric Sepsis
Interventions: For group Peds Sep A: Standard nutrition will be given, For Group Peds SepB: Low leucine, isoleucine formula, For Group Peds Sep C: Medium chain triglyceride oil enriched formula., For Group Peds Sep D: Low carbohydrate ketogenic formula; Dietary Supplement
Lead sponsor: University of Pittsburgh; Other
Eligibility: 44 Weeks to 17 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
Interventions: mRNA COVID-19, IIV4, Placebo (saline); Biological · Other
Lead sponsor: Duke University; Other
Eligibility: 5 Years and older
Enrollment: 348 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Baltimore, Maryland • Durham, North Carolina • Cincinnati, Ohio

Conditions: Septic Shock, Severe Sepsis
Interventions: Intravenous Fluid Cap; Other
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions: Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more

Conditions: Severe Sepsis
Interventions: Severe sepsis early warning best practice alert, Standard care; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cardiovascular Disease, Healthcare Associated Infectious Disease, Sternal Superficial Wound Infection, Deep Sternal Infection, Mediastinitis, Thoracotomy, Conduit Harvest or Cannulation Site, Sepsis, Pneumonia
Interventions: There is no intervention. The investigators are interviewing cardiac surgery staff with knowledge of infection prevention.; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: COVID-19, Hypoxia
Interventions: L-ascorbic acid; Drug
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Cardiomyopathies, Sepsis, Septic Shock
Interventions: Not listed
Lead sponsor: Samuel Brown; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Stanford, California • Murray, Utah

Conditions: Sepsis, Septic Shock, Healthy
Interventions: Blood collection; Device
Lead sponsor: Abionic SA; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Interventions: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours); Drug
Lead sponsor: Innoviva Specialty Therapeutics; Industry
Eligibility: 1 Day to 18 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • San Diego, California • Greenville, North Carolina + 1 more

Conditions: Fatigue, End Stage Renal Disease (ESRD)
Interventions: Lipidose, Placebo; Drug
Lead sponsor: Sepsicure; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Single Dose Enteral Tranexamic Acid in Critically Ill Patients

Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110

Muscle Atrophy in Sepsis

Noninvasive Assessment of Tissue Perfusion Status in Critically Ill Pediatric Patients

Safety and Efficacy of Baricitinib for COVID-19

Novel Mechanisms and Approaches to Treat Neonatal Sepsis

Comparing an Automated to a Conventional Sepsis Clinical Prediction Rule

Thrombin Generation and Thromboelastography in Non-overt DIC

Virulence Determinants in S Aureus Bacteremia

Multi-marker INDex for the Risk Assessment of Sepsis in the Emergency departmenT (MINDSET)

Ketamine Versus Etomidate for Rapid Sequence Intubation

Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer

Procalcitonin Levels as a Predictor of Bacteremia in Febrile Pediatric Oncology Patients-Pilot Study

Personalized Metabolic Nutrition Sepsis Study

Simultaneous mRNA COVID-19 and IIV4 Vaccination Study

Restrictive Intravenous Fluids Trial in Sepsis

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

Study of an Electronic Health Record-embedded Severe Sepsis Early Warning Alert

Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (HAI)_2

Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation

Translational Approaches to Septic Cardiomyopathy

Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

Lipid Infusion in Dialysis Patients With Endotoxemia